JP2013517330A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517330A5
JP2013517330A5 JP2012550125A JP2012550125A JP2013517330A5 JP 2013517330 A5 JP2013517330 A5 JP 2013517330A5 JP 2012550125 A JP2012550125 A JP 2012550125A JP 2012550125 A JP2012550125 A JP 2012550125A JP 2013517330 A5 JP2013517330 A5 JP 2013517330A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517330A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/021939 external-priority patent/WO2011091177A1/en
Publication of JP2013517330A publication Critical patent/JP2013517330A/ja
Publication of JP2013517330A5 publication Critical patent/JP2013517330A5/ja
Pending legal-status Critical Current

Links

JP2012550125A 2010-01-20 2011-01-20 抗ilt5抗体およびilt5結合抗体断片 Pending JP2013517330A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29679110P 2010-01-20 2010-01-20
US61/296,791 2010-01-20
PCT/US2011/021939 WO2011091177A1 (en) 2010-01-20 2011-01-20 Anti-ilt5 antibodies and ilt5-binding antibody fragments

Publications (2)

Publication Number Publication Date
JP2013517330A JP2013517330A (ja) 2013-05-16
JP2013517330A5 true JP2013517330A5 (enExample) 2014-03-06

Family

ID=44307212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550125A Pending JP2013517330A (ja) 2010-01-20 2011-01-20 抗ilt5抗体およびilt5結合抗体断片

Country Status (6)

Country Link
US (2) US9023997B2 (enExample)
EP (1) EP2525813B1 (enExample)
JP (1) JP2013517330A (enExample)
AU (1) AU2011207253B2 (enExample)
CA (1) CA2787783A1 (enExample)
WO (1) WO2011091177A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011091181A1 (en) * 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のFc領域改変体
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US10097315B2 (en) * 2013-04-19 2018-10-09 Qualcomm Incorporated Group scheduling and acknowledgement for wireless transmission
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
US9985802B2 (en) * 2014-10-31 2018-05-29 Qualcomm Incorporated Channel estimation enhancements
AU2016218900A1 (en) * 2015-02-11 2017-08-24 University Health Network Methods and compositions for modulating LILR proteins
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
JP2020511950A (ja) 2016-12-22 2020-04-23 アイカーン スクール オブ メディスン アット マウント シナイ 抗lilrb3抗体およびその使用の方法
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
EP3911680A4 (en) * 2019-01-18 2022-09-07 University Health Network LILRB3 BINDING MOLECULES AND ASSOCIATED USES
US20220233638A1 (en) * 2019-03-28 2022-07-28 Waseda University Cell competition inhibitor
IL295164A (en) * 2020-02-12 2022-09-01 Bioinvent Int Ab Antibody molecules against lilrb3 and their uses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61122292A (ja) 1984-11-16 1986-06-10 Teijin Ltd 新規カルバサイクリン中間体の製法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2001233003B2 (en) 2000-01-25 2006-02-09 Arca Biopharma, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
WO2001064839A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel macrophage nucleic acids and polypeptides
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002360376B2 (en) * 2001-11-14 2006-05-18 Immunex Corporation Modulation of LIR function to treat rheumatoid arthritis
US8071314B2 (en) 2001-12-14 2011-12-06 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders and therapeutic uses thereof
WO2005000901A2 (en) 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
AU2006249087B2 (en) 2005-05-20 2012-05-17 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CA2614640A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007092165A2 (en) 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
CN101415730B (zh) 2006-03-30 2013-04-10 诺瓦提斯公司 c-Met抗体的组合物和使用方法
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
EP2211903A4 (en) * 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
EP2220247A4 (en) 2007-11-16 2011-10-26 Nuvelo Inc ANTIBODY AGAINST LRP6
CN101971034A (zh) * 2007-12-11 2011-02-09 健泰科生物技术公司 神经元再生的调控剂
KR20110011676A (ko) 2008-05-13 2011-02-08 제넨테크, 인크. 항-PirB 항체
CL2009001155A1 (es) 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
JP5475766B2 (ja) 2008-06-30 2014-04-16 ユニバーシティ オブ ペンシルベニア Fn14/TRAIL融合タンパク質
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2012061620A1 (en) 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
TW201247700A (en) 2011-05-05 2012-12-01 Baylor Res Inst Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response

Similar Documents

Publication Publication Date Title
JP2013517330A5 (enExample)
JP2022031635A5 (enExample)
JP2010536384A5 (enExample)
JP2020180158A5 (enExample)
JP2021191763A5 (enExample)
JP2012502649A5 (enExample)
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
JP2020039360A5 (enExample)
JP2012525829A5 (enExample)
JP2009225799A5 (enExample)
JP2020508655A5 (enExample)
JP2020055849A5 (enExample)
JP2010513539A5 (enExample)
JP2018512379A5 (enExample)
JP2016529882A5 (enExample)
JP2016507523A5 (enExample)
JP2017052784A5 (enExample)
JP2010538608A5 (enExample)
JP2011517447A5 (enExample)
JP2011519571A5 (enExample)
JP2019504032A5 (enExample)
JP2013538057A5 (enExample)
JP2014503205A5 (enExample)
JP2014526898A5 (enExample)
JP2015514094A5 (enExample)